HighTower Advisors LLC Has $793,000 Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

HighTower Advisors LLC cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 54.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,594 shares of the biopharmaceutical company's stock after selling 19,580 shares during the quarter. HighTower Advisors LLC's holdings in Halozyme Therapeutics were worth $793,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $29,000. Smartleaf Asset Management LLC raised its stake in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $69,000. Parkside Financial Bank & Trust lifted its holdings in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Finally, Centaurus Financial Inc. acquired a new position in Halozyme Therapeutics in the third quarter valued at approximately $127,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the sale, the director now directly owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 over the last ninety days. Company insiders own 2.40% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Finally, Benchmark reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $62.78.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded down $0.03 during midday trading on Monday, reaching $63.81. 1,641,666 shares of the company traded hands, compared to its average volume of 1,378,292. The stock has a 50-day moving average price of $59.34 and a 200 day moving average price of $54.84. The company has a market cap of $7.88 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.